Laura Pellegrini
Overview
Explore the profile of Laura Pellegrini including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
2219
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhao T, Pellegrini L, van der Hee B, Boekhorst J, Fernandes A, Brugman S, et al.
Fluids Barriers CNS
. 2025 Feb;
22(1):14.
PMID: 39930492
Streptococcus suis is a globally emerging zoonotic pathogen that can cause invasive disease commonly associated with meningitis in pigs and humans. To cause meningitis, S. suis must invade the central...
2.
Tang S, Apsley E, Pellegrini L
Methods Mol Biol
. 2025 Jan;
PMID: 39821809
The choroid plexus (ChP) is a vital brain structure that produces cerebrospinal fluid (CSF) and forms a selective barrier between the blood and CSF, essential for brain homeostasis. Composed of...
3.
Zumerle S, Sarill M, Saponaro M, Colucci M, Contu L, Lazzarini E, et al.
Nat Aging
. 2024 Jul;
4(9):1231-1248.
PMID: 38951692
Accumulating senescent cells within tissues contribute to the progression of aging and age-related diseases. Botanical extracts, rich in phytoconstituents, present a useful resource for discovering therapies that could target senescence...
4.
Aventaggiato M, Arcangeli T, Vernucci E, Barreca F, Sansone L, Pellegrini L, et al.
Pharmaceuticals (Basel)
. 2024 Jun;
17(6).
PMID: 38931477
Cancer cells modulate their metabolism, creating an acidic microenvironment that, in turn, can favor tumor progression and chemotherapy resistance. Tumor cells adopt strategies to survive a drop in extracellular pH...
5.
Pellegrini L, Silva-Vargas V, Patrizi A
Fluids Barriers CNS
. 2024 May;
21(1):43.
PMID: 38773599
The European Choroid plexus Scientific Forum (ECSF), held in Heidelberg, Germany between the 7th and 9th of November 2023, involved 21 speakers from eight countries. ECSF focused on discussing cutting-edge...
6.
Chiaradia I, Imaz-Rosshandler I, Nilges B, Boulanger J, Pellegrini L, Das R, et al.
Cell Stem Cell
. 2023 Oct;
30(10):1351-1367.e10.
PMID: 37802039
Progression through fate decisions determines cellular composition and tissue architecture, but how that same architecture may impact cell fate is less clear. We took advantage of organoids as a tractable...
7.
Messina M, Crisciotti C, Pellegrini L, Nappi E, Racca F, Costanzo G, et al.
Vaccines (Basel)
. 2023 May;
11(5).
PMID: 37243013
Vaccines for SAR-CoV-2 are the most effective preventive treatment able to reduce the risk of contracting the infection and experiencing worse outcomes whenever the infection is contracted. Despite their rarity,...
8.
Alvarez-Arzola R, Bancaro N, Lai P, Attanasio G, Pellegrini L, Troiani M, et al.
Cell Commun Signal
. 2023 Apr;
21(1):76.
PMID: 37055829
Androgen deprivation therapy (ADT) is a standard therapy for prostate cancer (PCa). Though disseminated disease is initially sensitive to ADT, an important fraction of the patients progresses to castration-resistant prostate...
9.
Bononi A, Wang Q, Zolondick A, Bai F, Steele-Tanji M, Suarez J, et al.
Proc Natl Acad Sci U S A
. 2023 Jan;
120(4):e2217840120.
PMID: 36656861
is a powerful tumor suppressor gene characterized by haplo insufficiency. Individuals carrying germline mutations often develop mesothelioma, an aggressive malignancy of the serosal layers covering the lungs, pericardium, and abdominal...
10.
Lok S, de Boer R, Baron-Hay S, Button P, Devitt B, Forster B, et al.
Int J Cancer
. 2022 Aug;
152(2):267-275.
PMID: 36005450
The pertuzumab study in the neoadjuvant setting for HER2+ nonmetastatic breast cancer in Australia (PeRSIA-ML39622) is an analysis of safety and effectiveness data from the pertuzumab patient registry. Although the...